Project Grant R42CA290914
Award Date
6/23/25
Completion Date
5/31/26
Dollars Obligated
$400K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Connecticut, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to Tulane University is focused on investigating the role of the long non-coding RNA CRNDE in hepatocellular carcinoma (HCC) and its impact on tumor-infiltrating lymphocytes (TILs). The total award amount is $468,139, with a project period from March 15, 2025 to February 28, 2030. The key objectives of this research project are to elucidate the molecular mechanisms by which HCC-derived CRNDE...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) will support Phase I clinical testing of a novel therapeutic agent, termed MN-Anti-miR10B or TTX-MC138, developed by Transcode Therapeutics, Inc. The therapy aims to selectively target and eradicate metastatic tumor cells by inhibiting miRNA-10B, a validated driver of metastasis. Preclinical studies have shown the therapy can mediate regression of metastases in animal models with no evidence of...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) for $687,679 aims to functionally characterize the transcriptional regulatory landscape of hepatocellular carcinoma (HCC) in order to uncover novel tumor cell-intrinsic vulnerabilities. The research plan involves computationally establishing human HCC transcriptional master regulators (TMRs), validating their tumor cell-intrinsic functions using CRISPR interference and activation...
This Project Grant award, titled "EXPLOITING THERAPEUTIC VULNERABILITIES IN HEPATOCELLULAR CARCINOMA (ELEVATE)", is funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research). The $2,678,459 award aims to advance the understanding of molecular mechanisms regulating non-alcoholic steatohepatitis (NASH)-associated hepatocellular carcinoma (HCC) and develop novel combinatorial treatment approaches. The award supports four research projects, an administrative core, a...
The National Cancer Institute (NCI) awarded a $1,200,000 Project Grant under CFDA 93.395 - Cancer Treatment Research to Creative Biotherapeutics LLC, a biotechnology research firm, to develop a novel biologic therapy to eradicate brain cancer and brain metastases. The funded research aims to target the extracellular glucose-regulated protein 78 (eGRP78) expressed on the surface of drug-resistant tumor cells, in order to induce apoptosis, eliminate drug and immune resistance, and reduce the...
The National Cancer Institute (NCI) awarded a Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts. The $172,193 grant, awarded on May 7, 2025, supports a 5-year research project to characterize gene regulatory elements and metabolic functions in a rare and aggressive form of renal cell carcinoma known as translocation renal cell carcinoma (TRCC). The research aims to develop optimization methods to...
The National Cancer Institute (NCI) awarded a $177,000 Project Grant under the Cancer Biology Research program (CFDA 93.396) to The Children's Hospital Corporation, doing business as Boston Children's Hospital. The funding supports research to investigate the role of the NLRC4 inflammasome and caspase-8 activation in the pathogenesis of fibrolamellar carcinoma (FLC), a rare and aggressive form of liver cancer. The researchers will use mouse liver organoids engineered with the DNAJB1-PRKACA...
This federal Project Grant award of $400,000 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the advancement of next-generation CAR-T cell therapies for renal cell carcinoma (RCC). The award recipient, Cellinfinity Bio Inc., is developing novel CAR-T cell modifications, including a PRDM1 exon 3 knockout and a CTLA-4 cytoplasmic tail fusion, to enhance CAR-T cell efficacy against RCC tumors. The project aims to evaluate the combination of these...
This federal Project Grant award of $400,000 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of a short RNA therapeutic to treat ovarian cancer at Nuago Therapeutics Inc. in Chicago, IL. The award will fund research to create a novel, targeted therapy that aims to induce DNA damage in ovarian cancer cells. This project, running from June 2025 through May 2026, seeks to advance a potential new treatment approach that could improve outcomes for...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $793,324 to the Beckman Research Institute of the City of Hope to discover and validate CYP8B1 inhibitors as potential treatments for hepatocellular carcinoma (HCC). The project aims to: 1) identify CYP8B1 inhibitors through high-throughput screening of a 250,000-compound library; 2) validate hit compounds for potency, specificity, and structure-activity relationships; and 3)...